These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12819531)

  • 1. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
    Schnell T; Schmidt B; Moschik G; Thein C; Paatz C; Korn K; Walter H
    AIDS; 2003 May; 17(8):1258-61. PubMed ID: 12819531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
    Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
    AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
    Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.
    Colonno RJ; Thiry A; Limoli K; Parkin N
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1324-33. PubMed ID: 12654666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
    Bulgheroni E; Citterio P; Croce F; Lo Cicero M; Viganò O; Soster F; Chou TC; Galli M; Rusconi S
    J Antimicrob Chemother; 2004 Mar; 53(3):464-8. PubMed ID: 14963061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
    Noor MA; Parker RA; O'Mara E; Grasela DM; Currie A; Hodder SL; Fiedorek FT; Haas DW
    AIDS; 2004 Nov; 18(16):2137-44. PubMed ID: 15577646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
    Noor MA; Flint OP; Maa JF; Parker RA
    AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptidomimetic inhibitors of HIV protease.
    Randolph JT; DeGoey DA
    Curr Top Med Chem; 2004; 4(10):1079-95. PubMed ID: 15193140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
    Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
    Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
    Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
    AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 protease mutations and protease inhibitor cross-resistance.
    Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
    Young TP; Parkin NT; Stawiski E; Pilot-Matias T; Trinh R; Kempf DJ; Norton M
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4903-6. PubMed ID: 20805393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.
    Bierman WF; Scheffer GL; Schoonderwoerd A; Jansen G; van Agtmael MA; Danner SA; Scheper RJ
    J Antimicrob Chemother; 2010 Aug; 65(8):1672-80. PubMed ID: 20551216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
    Paulsen D; Elston R; Snowden W; Tisdale M; Ross L
    J Antimicrob Chemother; 2003 Sep; 52(3):319-23. PubMed ID: 12917233
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
    Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
    Yan Q; Hruz PW
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):398-403. PubMed ID: 16280693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
    Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
    J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
    Salcedo Gómez PM; Amano M; Yashchuk S; Mizuno A; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6110-21. PubMed ID: 24080647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.